Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab and AK117 in Metastatic Pancreatic Cancer
NCT06953999Phase 3Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivonescimab and ligufalimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Akeso, Inc. Primary endpoint: Overall Survival at 2 years. Started Jun 2025; status: recruiting.
02
Drugs
ivonescimabligufalimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06953999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06953999.